AGIOS PHARMACEUTICALS, INC. financials

AGIO CIK 0001439222

Source: EDGAR filings · Built 2026-06-02T02:15:55Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -377.29M -391.53M -297.06M -314.69M -413.64M -305.20M
EBITDA -466.93M -420.04M -384.89M -380.65M -369.62M -326.52M
Working Capital 859.85M 884.44M 765.88M 770.14M 1.00B 542.28M
Net Debt -48.92M -19.26M -16.21M -53.60M -106.03M -22.24M
Gross Margin 88.26% 88.59% 89.26% 88.03%
Operating Margin -873.87% -1166.47% -1459.52% -2732.07%
Net Margin -764.01% 1845.92% -1312.63% -1627.82%
Return on Equity (ROE) -34.60% 43.72% -43.41% -21.06% 124.21% -81.94%
Return on Assets (ROA) -31.82% 40.51% -37.57% -18.71% 111.61% -38.38%
Current Ratio 11.46× 11.90× 12.27× 13.30× 17.79× 6.74×
Debt-to-Equity 0.03× 0.04× 0.09× 0.08× 0.08× 0.26×
Effective Tax Rate 0.25% 6.16% 0.00% 0.00%
Cash Conversion Ratio 0.90× -0.58× 0.84× 1.34× -0.25× 0.89×
Accruals Ratio -0.03× 0.64× -0.06× 0.06× 1.40× -0.04×
SBC % of Revenue 97.27% 117.40% 166.89% 346.18%
CapEx Coverage -86.42× -231.36× -296.36× -59.38× -64.46× -20.13×
Free Cash Flow Per Share $-6.51 $-6.76 $-5.34 $-5.74 $-6.84 $-4.42

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 2.82× 1.24×
P/S 29.45× 51.46× 46.45× 108.53×
P/B 1.33× 1.22× 1.54× 1.40× 1.38× 7.52×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 54.03M 36.50M 26.82M 14.24M 0 0
Cost of Goods and Services Sold 6.34M 4.17M 2.88M 1.70M 0 0
Research and Development Expense 339.54M 301.29M 295.53M 279.91M 256.97M 220.81M
Selling, General and Administrative Expense 180.28M 156.78M 119.90M 121.67M 121.44M 115.11M
Operating Income (Loss) -472.13M -425.74M -391.49M -389.05M -378.42M -335.92M
Income Tax Expense (Benefit) -1.02M 44.24M 0 0
Net Income (Loss) Attributable to Parent -412.78M 673.73M -352.09M -231.80M 1.60B -327.37M
Earnings Per Share, Basic $-7.12 $11.86 $-6.33 $-4.23 $26.55 $-4.74
Weighted Average Number of Shares Outstanding, Basic 57.97M 56.81M 55.65M 54.79M 60.45M 69.00M
Earnings Per Share, Diluted $-7.12 $11.64 $-6.33 $-4.23 $26.55 $-4.74
Weighted Average Number of Shares Outstanding, Diluted 57.97M 57.89M 55.65M 54.79M 60.45M 69.00M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 89.13M 76.25M 88.20M 139.26M 203.13M 127.44M
Assets, Current 942.05M 965.60M 833.84M 832.77M 1.06B 636.68M
Assets 1.30B 1.66B 937.12M 1.24B 1.44B 852.95M
Liabilities, Current 82.21M 81.16M 67.95M 62.63M 59.83M 94.39M
Liabilities 104.11M 122.24M 126.10M 137.90M 145.76M 453.45M
Stockholders' Equity Attributable to Parent 1.19B 1.54B 811.02M 1.10B 1.29B 399.50M
Common Stock, Shares, Outstanding 58.45M 57.16M 55.95M 55.04M 54.33M 69.29M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -372.98M -389.84M -296.06M -309.48M -407.32M -290.76M
Payments to Acquire Property, Plant, and Equipment 4.32M 1.69M 999.00K 4.88M 5.74M 14.11M
Net Cash Provided by (Used in) Investing Activities 377.18M 363.44M 239.57M 243.26M 1.25B 75.75M
Net Cash Provided by (Used in) Financing Activities 8.68M 14.44M 5.43M 2.35M -765.77M 261.52M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (AGIO CIK 0001439222), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

LYFT

Lyft, Inc.

THRY

THRYV HOLDINGS, INC.

COGT

Cogent Biosciences, Inc.